Induction of robust immunity by the emulsification of recombinant lipidated dengue-1 envelope protein domain III

Microbes and Infection

Volumn 15, Issue 10-11, 2013, Pages 719-728

  Chiang, Chen Yi ^a   Huang, Ming Hsi ^a   Pan, Chien Hsiung ^a,b   Hsieh, Chun Hsiang ^a   Chen, Mei Yu ^a   Liu, Hsueh Hung ^a   Tsai, Jy Ping ^a   Liu, Shih Jen ^a,b   Chong, Pele ^a,b   Leng, Chih Hsiang ^a,b   Chen, Hsin Wei ^a,b  

^a NATIONAL HEALTH RESEARCH INSTITUTES   (Taiwan)

^b CHINA MEDICAL UNIVERSITY   (Taiwan)

Author keywords

Dengue; Immune response; Immunostimulation; Lipoprotein

Indexed keywords

ANTIGEN; B7 ANTIGEN; CD40 ANTIGEN; CD83 ANTIGEN; CD86 ANTIGEN; LIPOPROTEIN; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; NEUTRALIZING ANTIBODY; RECOMBINANT LIPIDATED DENGUE 1 ENVELOPE PROTEIN DOMAIN III; RECOMBINANT PROTEIN; SUBUNIT VACCINE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANTIGEN EXPRESSION; ARTICLE; CELLULAR IMMUNITY; DENGUE VIRUS 1; EMULSION; ESCHERICHIA COLI; HUMORAL IMMUNITY; IMMUNE RESPONSE; IMMUNITY; IMMUNOSTIMULATION; MACROPHAGE ACTIVATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN EXPRESSION; T LYMPHOCYTE; UPREGULATION;

BACTERIA (MICROORGANISMS); ESCHERICHIA COLI;

DENGUE; IMMUNE RESPONSE; IMMUNOSTIMULATION; LIPOPROTEIN;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; ANTIBODY AFFINITY; ANTIGENS, CD; CELL LINE; DENGUE VACCINES; DENGUE VIRUS; EMULSIONS; ESCHERICHIA COLI; GENE EXPRESSION; HISTOCOMPATIBILITY ANTIGENS CLASS II; LIPIDS; MACROPHAGE ACTIVATION; MACROPHAGES; MICE; MICE, INBRED BALB C; T-LYMPHOCYTES; VACCINES, SYNTHETIC; VIRAL ENVELOPE PROTEINS;

EID: 84884156051     PISSN: 12864579     EISSN: 1769714X     Source Type: Journal    
DOI: 10.1016/j.micinf.2013.06.002     Document Type: Article

References (44)

1. Hilleman M.R. Vaccines in historic evolution and perspective: a narrative of vaccine discoveries. Vaccine 2000, 18:1436-1447.
2. Pardoll D.M. Spinning molecular immunology into successful immunotherapy. Nat. Rev. Immunol. 2002, 2:227-238.
3. Reed S.G., Bertholet S., Coler R.N., Friede M. New horizons in adjuvants for vaccine development. Trends Immunol. 2009, 30:23-32.
4. Barton G.M., Medzhitov R. Toll-like receptors and their ligands. Curr. Top. Microbiol. Immunol. 2002, 270:81-92.
5. Iwasaki A., Medzhitov R. Toll-like receptor control of the adaptive immune responses. Nat. Immunol. 2004, 5:987-995.
6. Kato H., Takahasi K., Fujita T. RIG-I-like receptors: cytoplasmic sensors for non-self RNA. Immunol. Rev. 2011, 243:91-98.
7. Lamkanfi M., Kanneganti T.D. Regulation of immune pathways by the NOD-like receptor NLRC5. Immunobiology 2012, 217:13-16.
8. Williams A., Flavell R.A., Eisenbarth S.C. The role of NOD-like receptors in shaping adaptive immunity. Curr. Opin. Immunol. 2010, 22:34-40.
9. Erikci E., Gursel M., Gursel I. Differential immune activation following encapsulation of immunostimulatory CpG oligodeoxynucleotide in nanoliposomes. Biomaterials 2011, 32:1715-1723.
10. Thomann J.S., Heurtault B., Weidner S., Braye M., Beyrath J., Fournel S., Schuber F., Frisch B. Antitumor activity of liposomal ErbB2/HER2 epitope peptide-based vaccine constructs incorporating TLR agonists and mannose receptor targeting. Biomaterials 2011, 32:4574-4583.
11. Pashine A., Valiante N.M., Ulmer J.B. Targeting the innate immune response with improved vaccine adjuvants. Nat. Med. 2005, 11:S63-S68.
12. Huang M.H., Huang C.Y., Lien S.P., Siao S.Y., Chou A.H., Chen H.W., Liu S.J., Leng C.H., Chong P. Development of multi-phase emulsions based on bioresorbable polymers and oily adjuvant. Pharm. Res. 2009, 26:1856-1862.
13. Huang M.H., Lin S.C., Hsiao C.H., Chao H.J., Yang H.R., Liao C.C., Chuang P.W., Wu H.P., Huang C.Y., Leng C.H., Liu S.J., Chen H.W., Chou A.H., Hu A.Y., Chong P. Emulsified nanoparticles containing inactivated influenza virus and CpG oligodeoxynucleotides critically influences the host immune responses in mice. PLoS One 2010, 5:e12279.
14. Zhang Z., Tongchusak S., Mizukami Y., Kang Y.J., Ioji T., Touma M., Reinhold B., Keskin D.B., Reinherz E.L., Sasada T. Induction of anti-tumor cytotoxic T cell responses through PLGA-nanoparticle mediated antigen delivery. Biomaterials 2011, 32:3666-3678.
15. Cusi M.G. Applications of influenza virosomes as a delivery system. Hum. Vaccines 2006, 2:1-7.
16. Heffernan M.J., Zaharoff D.A., Fallon J.K., Schlom J., Greiner J.W. Invivo efficacy of a chitosan/IL-12 adjuvant system for protein-based vaccines. Biomaterials 2011, 32:926-932.
17. Chen H.W., Liu S.J., Liu H.H., Kwok Y., Lin C.L., Lin L.H., Chen M.Y., Tsai J.P., Chang L.S., Chiu F.F., Lai L.W., Lian W.C., Yang C.Y., Hsieh S.Y., Chong P., Leng C.H. A novel technology for the production of a heterologous lipoprotein immunogen in high yield has implications for the field of vaccine design. Vaccine 2009, 27:1400-1409.
18. Leng C.H., Chen H.W., Chang L.S., Liu H.H., Liu H.Y., Sher Y.P., Chang Y.W., Lien S.P., Huang T.Y., Chen M.Y., Chou A.H., Chong P., Liu S.J. A recombinant lipoprotein containing an unsaturated fatty acid activates NF-kappaB through the TLR2 signaling pathway and induces a differential gene profile from a synthetic lipopeptide. Mol. Immunol. 2010, 47:2015-2021.
19. Chiang C.Y., Liu S.J., Tsai J.P., Li Y.S., Chen M.Y., Liu H.H., Chong P., Leng C.H., Chen H.W. A novel single-dose dengue subunit vaccine induces memory immune responses. PLoS One 2011, 6:e23319.
20. Huang M.H., Chou A.H., Lien S.P., Chen H.W., Huang C.Y., Chen W.W., Chong P., Liu S.J., Leng C.H. Formulation and immunological evaluation of novel vaccine delivery systems based on bioresorbable poly(ethylene glycol)-block-poly(lactide-co-epsilon-caprolactone). J. Biomed. Mater. Res. B Appl. Biomater. 2009, 90:832-841.
21. Huang M.H., Huang C.Y., Lin S.C., Chen J.H., Ku C.C., Chou A.H., Liu S.J., Chen H.W., Chong P., Leng C.H. Enhancement of potent antibody and T-cell responses by a single-dose, novel nanoemulsion-formulated pandemic influenza vaccine. Microbes Infect. 2009, 11:654-660.
22. Chiang C.Y., Huang M.H., Hsieh C.H., Chen M.Y., Liu H.H., Tsai J.P., Li Y.S., Chang C.Y., Liu S.J., Chong P., Leng C.H., Chen H.W. Dengue-1 envelope protein domain III along with PELC and CpG oligodeoxynucleotides synergistically enhances immune responses. PLoS Negl. Trop. Dis. 2012, 6:e1645.
23. Macdonald R.A., Hosking C.S., Jones C.L. The measurement of relative antibody affinity by ELISA using thiocyanate elution. J. Immunol. Methods 1988, 106:191-194.
24. Nair N., Gans H., Lew-Yasukawa L., Long-Wagar A.C., Arvin A., Griffin D.E. Age-dependent differences in IgG isotype and avidity induced by measles vaccine received during the first year of life. J. Infect. Dis. 2007, 196:1339-1345.
25. Huang C.Y., Chen J.J., Shen K.Y., Chang L.S., Yeh Y.C., Chen I.H., Chong P., Liu S.J., Leng C.H. Recombinant lipidated HPV E7 induces a Th-1-biased immune response and protective immunity against cervical cancer in a mouse model. PLoS One 2012, 7:e40970.
26. Kwok Y., Sung W.C., Lin A.L., Liu H.H., Chou F.A., Hsieh S.S., Leng C.H., Chong P. Rapid isolation and characterization of bacterial lipopeptides using liquid chromatography and mass spectrometry analysis. Proteomics 2011, 11:2620-2627.
27. Chen Y., Maguire T., Hileman R.E., Fromm J.R., Esko J.D., Linhardt R.J., Marks R.M. Dengue virus infectivity depends on envelope protein binding to target cell heparan sulfate. Nat. Med. 1997, 3:866-871.
28. Hung J.-J., Hsieh M.-T., Young M.-J., Kao C.-L., King C.-C., Chang W. An external loop region of domain III of dengue virus type 2 envelope protein is involved in serotype-specific binding to mosquito but not mammalian cells. J. Virol. 2004, 78:378-388.
29. Shimizu T., Kida Y., Kuwano K. A triacylated lipoprotein from Mycoplasma genitalium activates NF-kappaB through toll-like receptor 1 (TLR1) and TLR2. Infect. Immun. 2008, 76:3672-3678.
30. Tawaratsumida K., Furuyashiki M., Katsumoto M., Fujimoto Y., Fukase K., Suda Y., Hashimoto M. Characterization of N-terminal structure of TLR2-activating lipoprotein in Staphylococcus aureus. J. Biol. Chem. 2009, 284:9147-9152.
31. Thakran S., Li H., Lavine C.L., Miller M.A., Bina J.E., Bina X.R., Re F. Identification of Francisella tularensis lipoproteins that stimulate the toll-like receptor (TLR) 2/TLR1 heterodimer. J. Biol. Chem. 2008, 283:3751-3760.
32. Bauer S., Kirschning C.J., Hacker H., Redecke V., Hausmann S., Akira S., Wagner H., Lipford G.B. Human TLR9 confers responsiveness to bacterial DNA via species-specific CpG motif recognition. Proc. Natl. Acad. Sci. U. S. A. 2001, 98:9237-9242.
33. Hemmi H., Takeuchi O., Kawai T., Kaisho T., Sato S., Sanjo H., Matsumoto M., Hoshino K., Wagner H., Takeda K., Akira S. A toll-like receptor recognizes bacterial DNA. Nature 2000, 408:740-745.
34. Takeshita F., Leifer C.A., Gursel I., Ishii K.J., Takeshita S., Gursel M., Klinman D.M. Cutting edge: role of toll-like receptor 9 in CpG DNA-induced activation of human cells. J. Immunol. 2001, 167:3555-3558.
35. de Alwis R., Smith S.A., Olivarez N.P., Messer W.B., Huynh J.P., Wahala W.M., White L.J., Diamond M.S., Baric R.S., Crowe J.E., de Silva A.M. Identification of human neutralizing antibodies that bind to complex epitopes on dengue virions. Proc. Natl. Acad. Sci. U. S. A. 2012, 109:7439-7444.
36. Wahala W.M., Silva A.M. The human antibody response to dengue virus infection. Viruses 2011, 3:2374-2395.
37. Guzman M.G., Hermida L., Bernardo L., Ramirez R., Guillen G. Domain III of the envelope protein as a dengue vaccine target. Expert Rev. Vaccines 2010, 9:137-147.
38. Leng C.H., Liu S.J., Tsai J.P., Li Y.S., Chen M.Y., Liu H.H., Lien S.P., Yueh A., Hsiao K.N., Lai L.W., Liu F.C., Chong P., Chen H.W. A novel dengue vaccine candidate that induces cross-neutralizing antibodies and memory immunity. Microbes Infect. 2009, 11:288-295.
39. Chen H.W., Liu S.J., Li Y.S., Liu H.H., Tsai J.P., Chiang C.Y., Chen M.Y., Hwang C.S., Huang C.C., Hu H.M., Chung H.H., Wu S.H., Chong P., Leng C.H., Pan C.H. A consensus envelope protein domain III can induce neutralizing antibody responses against serotype 2 of dengue virus in non-human primates. Arch. Virol. 2013.
40. Bernardo L., Izquierdo A., Alvarez M., Rosario D., Prado I., Lopez C., Martinez R., Castro J., Santana E., Hermida L., Guillen G., Guzman M.G. Immunogenicity and protective efficacy of a recombinant fusion protein containing the domain III of the dengue 1 envelope protein in non-human primates. Antivir. Res. 2008, 80:194-199.
41. Guzman M.G., Rodriguez R., Hermida L., Alvarez M., Lazo L., Mune M., Rosario D., Valdes K., Vazquez S., Martinez R., Serrano T., Paez J., Espinosa R., Pumariega T., Guillen G. Induction of neutralizing antibodies and partial protection from viral challenge in Macaca fascicularis immunized with recombinant dengue 4 virus envelope glycoprotein expressed in Pichia pastoris. Am. J. Trop. Med. Hyg. 2003, 69:129-134.
42. Robert Putnak J., Coller B.A., Voss G., Vaughn D.W., Clements D., Peters I., Bignami G., Houng H.S., Chen R.C., Barvir D.A., Seriwatana J., Cayphas S., Garcon N., Gheysen D., Kanesa-Thasan N., McDonell M., Humphreys T., Eckels K.H., Prieels J.P., Innis B.L. An evaluation of dengue type-2 inactivated, recombinant subunit, and live-attenuated vaccine candidates in the rhesus macaque model. Vaccine 2005, 23:4442-4452.
43. Simmons M., Porter K.R., Hayes C.G., Vaughn D.W., Putnak R. Characterization of antibody responses to combinations of a dengue virus type 2 DNA vaccine and two dengue virus type 2 protein vaccines in rhesus macaques. J. Virol. 2006, 80:9577-9585.
44. Velzing J., Groen J., Drouet M.T., van Amerongen G., Copra C., Osterhaus A.D., Deubel V. Induction of protective immunity against dengue virus type 2: comparison of candidate live attenuated and recombinant vaccines. Vaccine 1999, 17:1312-1320.